Table 3.

Multivariable analysis of quartiles of serum IGF-1 level and asthma outcomes in participants with asthma (n=34,023)

	All participants	Women	Men
IGF-1 quartile (Q), nmol/L	Odds Ratio (95% Confidence Interval)
Wheeze in the last year	n=21,991	n=12,477	n=9,514
Q1 (< 17.4)	1.0	1.0	1.0
Q2 (17.4– < 21.2)	0.88 (0.83–0.95)†	0.90 (0.82–0.97)*	0.87 (0.78–0.97)*
Q3 (21.2– < 24.8)	0.88 (0.83–0.95)†	0.89 (0.82–0.98)*	0.87 (0.78–0.97)*
Q4 (≥ 24.8)	0.89 (0.83–0.96)†‡	0.92 (0.84–1.00)	0.87 (0.78–0.97)*‡
At least one asthma-related hospitalization	n=1,086	n=713	n=373
Q1 (< 17.4)	1.0	1.0	1.0
Q2 (17.4– < 21.2)	0.98 (0.82–1.16)	0.95 (0.77–1.17)	1.04 (0.75–1.44)
Q3 (21.2– < 24.8)	1.18 (0.99–1.40)	1.17 (0.95–1.44)	1.23 (0.90–1.68)
Q4 (≥ 24.8)	0.97 (0.81–1.17)	0.87 (0.69–1.10)	1.17 (0.85–1.62)

Abbreviation: IGF-1, insulin-like growth factor 1

All models adjusted for sex (in all participants), age, ethnicity, annual household income, body mass index, smoking status, pack-years of cigarette smoking, the season of the examination, the time of the day when the examination was performed, serum level of glycated hemoglobin A1c, and C-reactive protein.

^*P <0.5

^†P <0.01

^‡P for trend <0.05